Lilly looks to enter major market with new lung cancer combo

13 March 2019
lilly-logo-big

More positive Phase III data for Eli Lilly’s (NYSE: LLY) Cyramza (ramucirumab) will support a mid-2019 regulatory push into non-small cell lung cancer (NSCLC).

Shares in the firm traded around 1.5% higher by the closing bell on Tuesday, after the firm announced the RELAY trial met its primary endpoint of progression-free survival.

The trial is testing the VEGF receptor 2 agonist, in combination with Roche (ROG: SIX) and Astellas Pharma’s (TYO: 4503) targeted therapy Tarceva (erlotinib), as a first-line treatment for certain people with NSCLC. Detailed results will be presented later in the year.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical